Note: Specific details of MIRD-226 are subject to change based on the hosting agency and year of execution. This article synthesizes public training objectives, equipment standards, and after-action themes common to the MIRD series as of 2026.
MIRD-226, published in 2009, is a comprehensive report that provides absorbed dose estimates for a variety of radiopharmaceuticals. The report presents dose estimates for radiopharmaceuticals used in diagnostic and therapeutic applications, including those used in oncology, cardiology, and neurology. MIRD-226 serves as a valuable resource for nuclear medicine professionals, providing them with data to assess the risks and benefits associated with radiopharmaceutical administration.
¹³¹I is a beta emitter with a physical half-life of approximately 8 days. It is selectively taken up by the thyroid gland, where it destroys thyroid tissue. This selective uptake makes ¹³¹I an ideal therapeutic agent for thyroid diseases, offering a targeted approach to treatment with minimal impact on surrounding tissues.